Loading
A phase 1/2 trial of FOLFIRI, Irinotecan, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by Marengo Therapeutics, Inc., now recruiting.
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05592626 by Marengo Therapeutics, Inc., with 366 participants planned, started 2023-01-04 and due to reach its primary completion in 2027-09. Interventions recorded: STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere). Conditions listed: Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Docetaxel, Small-cell lung cancer, Colorectal cancer, Non-small-cell lung cancer.
Shares Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Small-cell lung cancer.
Shares Docetaxel, Small-cell lung cancer, Colorectal cancer, Non-small-cell lung cancer.
Shares Irinotecan (and liposomal irinotecan), FOLFIRI (5-FU, leucovorin, irinotecan), Colorectal cancer.
Shares Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/